Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Afri…
$103.21-1.29%
报价 2026-11-13
市值
$19.53B
EV
$27.44B
PE (TTM)
27.1x
预期 PE (FY2026)
12.1x
52 周区间距高点 -6.3%
$79.58$110.15
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 8.48 → 8.98（1.1x） | 11.5 |
| FY+32028-12 | 1.1x | 8.48 → 9.65（1.1x） | 10.7 |
毛利率 70% · TTM 收入 $8570M · 基数 EPS 8.48（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ZBHZimmer Biomet Holdings, Inc. | $19.53B | -1.3% | +4.9% | 71.2% | 27.1x | 12.0x | 12.3x | |
| WATWaters Corporation | $45.24B | -0.4% | +105.3% | 58.9% | 28.0x | 18.3x | 155.1x | 高增长 |
| ILMNIllumina, Inc. | $31.3B | -1.2% | +7.6% | 66.4% | 49.5x | 30.8x | 43.1x | |
| DXCMDexCom, Inc. | $31.08B | +2.4% | +12.4% | 63.4% | 34.4x | 21.8x | 23.9x | GARP |
| LHLabcorp Holdings Inc. | $30.08B | -0.5% | +6.0% | 29.8% | 27.6x | 15.9x | 23.9x | |
| WSTWest Pharmaceutical Services, Inc. | $29.01B | +1.2% | +11.6% | 39.7% | 45.5x | 29.2x | 62.7x | |
| DGXQuest Diagnostics Incorporated | $28.56B | -0.0% | +10.0% | 33.7% | 24.3x | 15.6x | 21.0x | GARP |
| STESTERIS plc | $25.67B | +4.3% | +7.3% | 44.7% | 30.3x | 17.2x | 26.6x | |
| UTHRUnited Therapeutics Corporation | $25.18B | -0.4% | +1.6% | 86.1% | 17.9x | 12.8x | 21.0x | |
| 同行中位数 | – | – | +8.8% | 51.8% | 29.1x | 17.7x | 25.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.06B | $2.18B | $2.09B | $2.24B | $2B | $2.08B | $1.91B | $2.02B |
| Gross Margin | 71.2% | 70.8% | 72.4% | 64.7% | 72.1% | 71.5% | 71.2% | 71% |
| Operating Margin | 14.9% | 15% | 17.9% | 12.8% | 17.6% | 14.4% | 15.3% | 19.2% |
| Net Income | $191.6M | $198.3M | $238.1M | $139.5M | $230.9M | $152.8M | $182M | $239.5M |
| Diluted EPS | 1 | 1.03 | 1.22 | 0.7 | 1.16 | 0.77 | 0.91 | 1.2 |
| Operating Cash Flow | $560.1M | $447.8M | $359.4M | $517.3M | $418.7M | $378.2M | $382.8M | $506.3M |